At CDR-Life, we are on a mission to transform antibody science into life-changing therapies. Our innovative T Cell Engager (TCE) platform, M-GAGER®, delivers therapeutics against challenging targets with unprecedented precision, speed, and efficiency. For cancer patients, we are advancing a pipeline of potent and selective TCEs targeting intracellular and surface antigens that empower patients’ own immune systems to eliminate tumors, and our first program has entered the clinic. In autoimmune diseases, we're using this same breakthrough approach to reset overactive immune responses with pinpoint accuracy. Our platform combines optimized manufacturability with deep scientific expertise and cutting-edge engineering, enabling rapid translation from discovery to scalable production of these complex biologics. This integrated approach helps accelerate the journey from lab to patient treatment, making once-impossible therapeutic goals both achievable and deliverable at scale.
Something looks off?